In the BioHarmony Drug Report Database

"Preview" Icon

Relebactam

Recarbrio (relebactam) is a small molecule pharmaceutical. Relebactam was first approved as Recarbrio on 2019-07-16. It is used to treat intraabdominal infections, pyelonephritis, and urinary tract infections in the USA. It has been approved in Europe to treat gram-negative bacterial infections. Recarbrio’s patent is valid until 2029-11-19 (FDA).

 

Trade Name

 

Recarbrio
 

Common Name

 

relebactam
 

ChEMBL ID

 

CHEMBL3301605
 

Indication

 

gram-negative bacterial infections, intraabdominal infections, pyelonephritis, urinary tract infections
 

Drug Class

 

Beta-lactamase inhibitors

Image (chem structure or protein)

Relebactam structure rendering